Anavex Life Sciences (AVXL) Amortization of Deferred Charges (2010 - 2014)

Anavex Life Sciences (AVXL) has 4 years of Amortization of Deferred Charges data on file, last reported at $1.1 million in Q3 2014.

• For the quarter ending Q3 2014, Amortization of Deferred Charges changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2015 stood at $1.1 million (up 11083.56% YoY), and the FY2014 full-year result was $1.1 million, up 92378.35% from the prior year.
• Amortization of Deferred Charges rose to $1.1 million in Q3 2014, from $8848.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.1 million in Q3 2014 to a low of $1199.0 in Q1 2014.
• A 4-year average of $126207.7 and a median of $17449.0 in 2011 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges surged 46.91% in 2011 and sank 96.22% in 2012, its largest moves.
• Tracing AVXL's Amortization of Deferred Charges over 4 years: stood at $30315.0 in 2010, then sank by 35.17% to $19654.0 in 2011, then plunged by 93.82% to $1215.0 in 2012, then surged by 91551.44% to $1.1 million in 2014.
• Business Quant data shows AVXL's Amortization of Deferred Charges at $1.1 million in Q3 2014, $8848.0 in Q2 2014, and $1199.0 in Q1 2014.